**Core Concept**
Monoclonal antibodies targeting nerve growth factor (NGF) have been developed to treat chronic pain conditions, including osteoarthritis and chronic low back pain. This class of medications aims to modulate pain transmission by inhibiting the action of NGF, a key player in nociception and pain processing.

**Why the Correct Answer is Right**
The correct answer, **Nerivio (A)**, is a monoclonal antibody that targets the 75-kDa subunit of NGF, preventing its interaction with the p75NTR receptor. This mechanism of action leads to a reduction in NGF-mediated pain signaling, resulting in decreased pain perception in patients with osteoarthritis and chronic low back pain. **Nerivio** has been shown to be effective in reducing pain and improving quality of life in these patient populations.

**Why Each Wrong Option is Incorrect**
**Option A:** **Nerivio** is correct, as explained above.
**Option B:** There is no evidence to support the use of **Omalizumab** (a monoclonal antibody against IgE) in chronic pain management.
**Option C:** **Rituximab** (a monoclonal antibody against CD20) is used in the treatment of autoimmune diseases, such as rheumatoid arthritis, but not for chronic pain.
**Option D:** **Trastuzumab** (a monoclonal antibody against HER2) is used in the treatment of breast cancer, not for chronic pain.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that monoclonal antibodies targeting NGF, like **Nerivio**, are a relatively new class of medications for chronic pain management. These agents offer a novel mechanism of action and have shown promise in reducing pain in patients with osteoarthritis and chronic low back pain.

**Correct Answer:** C.